LAIYANG, China, Feb. 22, 2011 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that the Company will host a conference call at 9:00 a.m. Eastern Standard Time on Wednesday, February 23, 2011 to discuss financial results for the second quarter fiscal 2011 ended December 30, 2010.
The conference call will be hosted by Mr. Linxian Jin, CEO, and Ms. Elsa Sung, CFO, of Jiangbo.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (866) 395-5819. International callers should dial +1 (706) 643-6986. The Conference ID for this call is 45929313.
If you are unable to participate on the live call, a replay will be available for 14 days starting on Wednesday, February 23, 2011 at 11:00 a.m. Eastern Standard Time. To access the replay, dial (800) 642-1687, international callers dial (706) 645-9291. The Conference ID is 45929313.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (http://www.jiangbopharma.com/).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to execute its strategic plan. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Contact: Jiangbo Pharmaceuticals, Inc. CCG Investor Relations Ms. Elsa Sung, CFO Mr. Crocker Coulson, President Phone: (954) 903-9378 ex 2 Phone: (646) 213-1915 E-mail:elsasung@jiangbo.com E-mail: crocker.coulson@ccgir.com http://www.jiangbopharma.com/ http://www.ccgirasia.com/
Jiangbo Pharmaceuticals, Inc.
CONTACT: Jiangbo Pharmaceuticals, Inc., Ms. Elsa Sung, CFO,
+1-954-903-9378 ex 2, elsasung@jiangbo.com; or CCG Investor Relations, Mr.
Crocker Coulson, President, +1-646-213-1915, crocker.coulson@ccgir.com
Web Site: http://www.jiangbopharma.com/
